Pharmaceutical patents | Intellepedia

Latest Patent Cases in 2021 – Part 2

This article summarises pivotal Delhi High Court decisions on patent disputes in 2021, particularly involving pharmaceutical products. The analysis covers interim injunctions and key arguments in Indian patent litigation.

Latest Patent Cases in 2021 – Part 1

The H. Lundbeck A/S vs Symed Labs Limited case involved a pre-notice settlement of a patent dispute, with the Delhi High Court decreeing the suit on agreed terms. The settlement clarifies the scope of Section 107A use and sets compliance and reporting obligations for the defendant.

Delhi High Court asks government to consider issuing compulsory licenses, World IP day 2021, a solemn affair this year, India – South Africa patent waiver proposal opposed again and more

The Delhi High Court has advised the government to consider compulsory licensing of COVID-19 treatments, reflecting the urgent need for wider access. This post also covers the global debate on patent waivers and the observance of World IP Day 2021, with a focus on recent legal and policy updates.

Indian Patent Cases and Judgments of 2020

A detailed review of major Indian patent cases and judgments from 2020, addressing core issues in patent opposition, litigation, and enforcement. The analysis offers insights into judicial trends and key legal standards shaping Indian patent law.

Compulsory Licensing in India – Talk by Gaurav Mishra

Mr. Gaurav Mishra presented an in-depth session on compulsory licensing in India under the Patents Act at a DST Rajasthan event. The talk covered legal provisions, case studies, and the significance of compulsory licensing during the COVID-19 pandemic.

COVID-19 patent pool opposed as Pfizer and AstraZeneca see no incentive and other patent news

This bulletin provides updates on the COVID-19 patent pool, opposition from leading pharmaceutical companies, and key patent law changes in India and abroad. It includes IPO e-filing developments, WHO C-TAP news, and significant international patent infringement cases.

Innovate, Patent, Produce and Prosper says PM, Natco Pharma faces patent infringement law suit and more

This bulletin highlights Prime Minister Modi’s emphasis on innovation and patenting, the upcoming GIPC in New Delhi, and crucial legal updates such as Taiho Pharmaceutical’s lawsuit against Natco Pharma. Important decisions from the Indian Patent Office and international appointments are also covered.

Chapter II. 301 Report on Indian Patent System – Comprehending Apprehension or Apprehending Comprehension?

The 2014 Special 301 Report reviews India’s patent system, focusing on Section 3d, compulsory licensing, and enforcement issues. This analysis sets the groundwork for deeper exploration of key pharmaceutical patent law topics in future posts.

Inventive Step of an Invention Analysed

This post examines the Green Cross Holdings case, where the Indian IPAB upheld the rejection of a patent application for lacking inventive step. The analysis highlights legal standards of obviousness and inventive step under Indian patent law, emphasizing the importance of prior art disclosure.

Exclusive Marketing Rights and Stronger Patent Regime

This post examines India’s transition to a TRIPS-compliant patent regime, focusing on Exclusive Marketing Rights and the Mailbox Provision. It outlines legislative changes that facilitated the shift from process to product patents and clarifies the distinct role of EMRs during this period.